Karl Baisch GmbH has been acquired by Friedrich Ziegler GmbH
Friedrich Ziegler GmbH, a manufacturer of furniture for a variety of industries such as medical rooms, kitchens and stores, has acquired the intangible assets of Karl Baisch GmbH within an asset deal. Financial details of this transaction have not been disclosed.
Karl Baisch GmbH is the leading manufacturer of dental furniture in Europe's German-speaking countries. The company has experienced financial difficulties for a number of years due to internal structural problems and the changing market environment. Despite the implementation of various measures to stabilise the business, the company has been unable to achieve a sustainable turnaround and was forced to file for insolvency.
Dr. Hendrik Hefermehl from Stuttgart has been appointed as the insolvency administrator.
Oaklins' team in Germany was commissioned exclusively by the insolvency administrator to provide assistance on the transfer of the company and its assets.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Learn more